Form 4: Berkshire Hathaway Sells $230M DaVita Shares

Berkshire Hathaway Inc., a 10% owner of DaVita Inc., has filed to sell 1,635,962 shares of common stock for approximately $230 million.

Summary

• Berkshire Hathaway Inc. and Warren E. Buffett, as a 10% owner and director, reported a planned sale of DaVita Inc. common stock.
• The transaction involves the disposition of 1,635,962 shares of common stock.
• The sale price per share is $140.6052.
• The total value of the shares sold is approximately $230 million.
• Following this transaction, Berkshire Hathaway and its related entities will beneficially own 32,160,579 shares of DaVita common stock.
• The sale is scheduled for July 31, 2025, and appears to be part of a pre-arranged Rule 10b5-1 plan.

Sentiment

Score: 3

Explanation: A large sale by a significant and influential investor like Berkshire Hathaway, even if pre-planned, typically generates negative sentiment as it can be interpreted as a reduction in confidence or a strategic portfolio shift, potentially putting downward pressure on the stock price.

Negatives

• A significant sale of 1,635,962 shares by a major, influential investor like Berkshire Hathaway could signal a reduction in conviction or a strategic portfolio rebalancing.
• The sale represents approximately $230 million in value, which is a substantial divestment.

Future Outlook

The filing indicates a pre-planned sale of shares under a Rule 10b5-1 plan, scheduled for July 31, 2025, suggesting a long-term strategic decision rather than an immediate reaction to market conditions.

Management Comments

• Warren E. Buffett, on behalf of himself and each other reporting person hereunder, signed the filing.

Industry Context

DaVita Inc. operates in the healthcare services industry, primarily providing kidney dialysis services. A significant divestment by a major investor like Berkshire Hathaway could be interpreted by the market as a re-evaluation of the long-term prospects within the healthcare sector or DaVita specifically, though the filing itself does not provide explicit reasons.

Related Party Transactions

• The transaction involves the sale of shares by Berkshire Hathaway Inc., a 10% owner and entity with director representation, to the open market, which is a common type of related party transaction in the context of insider filings.

Stakeholder Impact

• Shareholders may react negatively to the news of a major investor reducing its stake, potentially leading to a decrease in share price due to perceived reduced confidence.
• Employees, customers, suppliers, and creditors are unlikely to be directly impacted by this specific insider transaction, though a significant stock price decline could indirectly affect morale or perception.

Key Dates

Recommendation

While a significant sale by a major investor like Berkshire Hathaway is a negative signal, the transaction is pre-planned under Rule 10b5-1 and scheduled for a future date (July 2025). This suggests a strategic portfolio adjustment rather than an immediate reaction to adverse company news. Investors should monitor DaVita's operational performance and broader industry trends rather than making an immediate 'sell' decision based solely on this pre-scheduled insider sale. A 'hold' recommendation allows for observation of future developments.

Keywords

Berkshire Hathaway, DaVita Inc., DVA, Warren Buffett, Stock Sale, Insider Trading, Form 4, Healthcare, Dialysis, Investment